Camber launches generic Hyzaar tablets
The product is the generic equivalent of Hyzaar and combines an angiotensin II receptor blocker with a diuretic.
Camber Pharmaceuticals
Camber has introduced Losartan Potassium and Hydrochlorothiazide Tablets
Losartan Potassium and Hydrochlorothiazide is a combination of an angiotensin II receptor blocker and diuretic.
Camber Specialty marks first Day 1 injectable launch
“This milestone reflects our commitment to expanding access to high-quality injectable products that support healthcare providers and their patients,” said Tom DeStefano, Vice President of Specialty Sales.
Camber has released Nitazoxanide Tablets
Nitazoxanide Tablets are antiprotozoal indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Camber launches generic Nimbex injection
The launch expands Camber’s hospital and acute care products and provides healthcare providers access to a widely used neuromuscular blocking agent for anesthesia and critical care.
Camber strengthens portfolio with the launch of five new generic medications in May
By expanding treatment options and increasing availability of essential therapies, Camber continues to support healthcare providers, pharmacies, and patients across the country.
Q&A with Kon Ostaficiuk, President, Camber Pharmaceuticals
Camber Pharmaceuticals aims to expand in the U.S. generics market. President Kon Ostaficiuk highlights a strategy focused on scale, speed, and competitiveness.
Camber offers Q1 recap
New launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
Camber expands portfolio
New launches of Plerixafor Injection, Baclofen Tablets, Fluvoxamine Maleate ER Capsules, and Olmesartan Hydrochlorothiazide Tablets.
Camber Pharmaceuticals launches Pomalidomide Capsules
Pomalidomide capsules are available in 1 mg, 2 mg, 3 mg, and 4 mg strengths in bottles of 21 capsules.
Camber launches Sodium Oxybate Oral Solution
Sodium Oxybate Oral Solution 0.5 g/mL is available in 180 mL bottles and is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy.
Camber launches Voriconazole for oral suspension
Voriconazole for Oral Suspension treats yeast and fungal infections in adults and children 2 years and older, especially in cases of intolerance or resistance to other treatments.
Camber launches Spironolactone Tablets
Spironolactone Tablets are indicated for treatment of Heart Failure, Hypertension, Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome, and Primary Hyperaldosteronism.
Camber Pharmaceuticals reviews 2025 achievements and plans 2026 growth
Camber’s year featured broad generic launches, specialty and oncology introductions, emphasizing access, affordability, and supply reliability in the U.S.
Camber awarded 2025 “Large Supplier of the Year” by the Premier Group
“This award is a direct result of strong collaboration and shared accountability,” said Stu Messinger, Director of National Accounts.
Camber launches Nilotinib capsules
Camber Pharmaceuticals continues to strengthen its range of treatment options.